Phase 2 N=23 Study of Nicotinamide in Early Onset Preeclampsia
Pre-Eclampsia · Pregnancy Related
Primary: Change in Mean Arterial Blood Pressure (MAP) — 0; 2; 4 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 CX-8998 for Absence Seizures
Epilepsy
Primary: Change From Baseline to End of Treatment in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) — 3.50 msec
Phase 2 N=76 A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Efficacy: Mean Changes in FVC From Baseline to Week 24 — 2608.2; 2516.7; 2608.8; 2516.7 mL
N/A N=31 Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
COVID19
Primary: Primary Safety Measure — 0; 0 Participants
Phase 4 N=46 Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study
PostTraumatic Stress Disorder
Primary: Brain Measures — 0.039567327; 0.092173636; 0.149446357; -0.021618 arbitrary units — p=< 0.05
Phase 3 N=1,279 S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 81.1; 70.2 months — p=.080
Phase 2 N=29 Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery
Cardiac Surgery Subjects · Subjects Undergoing CABG and/or Cardiac Valve Replacement
Primary: Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 0.5 Hour Post-separation From Cardiopulmonary Bypass (CPB) — -7.75; -10.94; 62.22 percent change…
N/A N=38 The Evaluation of a Full Face Mask Seal for the Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Trial Mask Seal Comfort — 16; 13; 16; 19 Participants
Phase 2 N=21 Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
PCDH19-Related Epilepsy
Primary: Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change) — -23.97; -61.52 Median % Change in Number of Seizures
N/A N=167 A Computer-Assisted CBT Tool to Enhance Fidelity in CBOCs
Depression
Primary: CBT Treatment Fidelity (a Rating Indicating Provider Overall Competence in Delivering the Intervention) — 3.99; 3.23 scores on a scale
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
Phase 4 N=333 Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Primary Adverse Events (PAEs) — 11; 3 Participants
Phase 2 N=88 Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
HER2-negative Breast Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC) — 38.2; 61.9 Percentage of participants — p=0.0210
N/A N=34 Microelectrodes in Epilepsy
Epilepsy
Primary: Feasibility of Microelectrode Technology to Isolate Place Responsive Neurons in the Human Hippocampus as Measured by the Number of Place Responsive Neurons. — 79 place…
N/A N=61 e۰Sense® Catheter Clinical Investigation
Urodynamics
Primary: Clinician Safety and Effectiveness Rating of eSense Catheters (Per Patient) — 58 Participants